[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580813":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":37,"centralContacts":42,"locations":48,"responsibleParty":144,"collaborators":36,"id":146,"slug":147,"hasResults":148,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":154,"sex":155,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":36,"studyType":161,"phases":162,"briefSummary":165,"conditions":166,"keywords":36,"overallStatus":51,"whyStopped":36,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},{"fullName":5,"class":6},"Wave Life Sciences USA, Inc.","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Part A: Experimental WVE-007 (Dose 1) or Placebo Part B Pre-T2D: Experimental WVE-007 (Dose 1) or Placebo",[13],"Drug: WVE-007",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","Part A: Experimental WVE-007 (Dose 2) or Placebo Part B Pre-T2D: Experimental WVE-007 (Dose 2) or Placebo",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","Part A: Experimental WVE-007 (Dose 3) or Placebo",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4","Part A: Experimental WVE-007 (Dose 4) or Placebo Part B T2D: Experimental WVE-007 (Dose 4) or Placebo",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Cohort 5","Part A: Experimental WVE-007 (Dose 5) or Placebo Part B T2D: Experimental WVE-007 (Dose 5) or Placebo",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","WVE-007","Stereopure siRNA oligonucleotide",[9,15,19,23,27],null,[38],{"name":39,"affiliation":40,"role":41},"Medical Director, MD","Wave Life Sciences","STUDY_DIRECTOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":36,"email":47},"Clinical Operations","CONTACT","855-215-4687","Clinicaltrials@wavelifesci.com",[49,68,84,100,114,130],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Parexel International-EPCU Baltimore","RECRUITING","Baltimore","Maryland","21225","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-76.61219,39.29038,{"lat":61,"lon":60},[64],{"name":65,"role":45,"phone":66,"phoneExt":36,"email":67},"Ronald Goldwater, M.D.","877-617-8839","study.baltimore@parexel.com",{"facility":69,"status":51,"city":70,"state":36,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"ARENSIA Research Clinic","Chisinau","MD-2025","Moldova","MD",{"type":58,"coordinates":75},[76,77],28.85938,47.00902,{"lat":77,"lon":76},[80],{"name":81,"role":45,"phone":82,"phoneExt":36,"email":83},"Maxim Bogus","373 78883374","Maxim.bogus@arensia-em.com",{"facility":85,"status":51,"city":86,"state":36,"zip":87,"country":88,"countryCode":89,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Arensia Clinics S.R.L.","Bucharest","011658","Romania","RO",{"type":58,"coordinates":91},[92,93],26.10626,44.43225,{"lat":93,"lon":92},[96],{"name":97,"role":45,"phone":98,"phoneExt":36,"email":99},"Simona Macovei","+40711912918","simona.macovei@arensia-em.com",{"facility":101,"status":51,"city":102,"state":36,"zip":103,"country":88,"countryCode":89,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Spitalul Clinic Judetean De Urgenta Cluj","Cluj-Napoca","400006",{"type":58,"coordinates":105},[106,107],23.6,46.76667,{"lat":107,"lon":106},[110],{"name":111,"role":45,"phone":112,"phoneExt":36,"email":113},"Emanuela Beni","+40711912839","emanuela.beni@arensia-em.com",{"facility":115,"status":51,"city":116,"state":36,"zip":117,"country":118,"countryCode":119,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Parexel International Early Phase Clinical Unit","Harrow","HA1 3UJ","United Kingdom","UK",{"type":58,"coordinates":121},[122,123],-0.33208,51.57835,{"lat":123,"lon":122},[126],{"name":127,"role":45,"phone":128,"phoneExt":36,"email":129},"Pablo Forte","01895 614 890","Pablo.ForteSoto@parexel.com",{"facility":131,"status":51,"city":132,"state":36,"zip":133,"country":118,"countryCode":119,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Simbec-Orion Clinical Pharmacology","Merthyr Tydfil","CF48 4DR",{"type":58,"coordinates":135},[136,137],-3.37779,51.74794,{"lat":137,"lon":136},[140],{"name":141,"role":45,"phone":142,"phoneExt":36,"email":143},"Annelize Koch","01685 700870","Annelize.koch@simbecorion.com",{"type":145,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100580813","phase-1-a-phase-12a-study-of-wve-007-in-adults-living-with-overweight-or-obesity-100580813",false,"NCT06842186","A Phase 1\u002F2a Study of WVE-007 in Adults Living With Overweight or Obesity","A Phase 1\u002F2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity","INLIGHT","Inclusion Criteria: Part A\n\n* Male and female participants aged 18 to 60 years\n* BMI 28 to 35 kg\u002Fm2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records). For participants considered for enrollment in a cohort expansion, BMI 28 to 40 kg\u002F m2 will be allowed.\n* Healthy, in the opinion of the Investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments\n\nInclusion Criteria : Part B\n\n* Male and female participants aged 18 to 60 years\n* BMI 35 to 50 kg\u002Fm2 (inclusive)\n* Thyroid stimulating hormone is within normal range at Screening. May be on supplemental thyroid hormone as managed by their prescribing physician and stable within the last 60 days\n* Have Pre T2D or T2D\n\nExclusion Criteria: Part A\n\n* History or presence of CV disease, including heart failure (New York Heart Association \\[NYHA\\] Class III or IV), myocardial infarction, angina, or clinically significant abnormal laboratory assessments\n* History or presence of thyroid disorders\n* Medical history or diagnosis of causes of liver disease\n* Use of any siRNA agent in the prior 12 months\n* Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study\n\nExclusion Criteria: Part B\n\n* History of significant CV disease in the opinion of the Investigator.\n* Use of prescription medications (ie, anti-obesity or psychiatric medications) within 14 days or 7 half-lives (whichever is longer) before the first dose of study drug, except for allowed antihypertensive medications and statins.\n* Taking \\>2 antihypertensive medications, or antihypertensive medication dose was changed in the 60 days prior to Screening.\n* Taking \\>1 cholesterol-lowering medication, or cholesterol-lowering medication dose was changed in the 60 days prior to Screening.\n* Cohorts 1 and 2 (preT2D) only: use of any GLP-1 receptor agonists or dual incretin agonists within the 4 months prior to Screening.\n* Cohorts 4 and 5 (T2D) only: use of insulin or any medication that directly stimulates pancreatic insulin within the 60 days prior to Screening, including sulfonylureas, meglitinides, GLP-1 receptor agonists, dual incretin agonists, and DPP-4 inhibitors.\n* Use of any siRNA agent in the prior 12 months.\n* Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study.",true,"ALL","18 Years","60 Years",{"count":159,"type":160},296,"ESTIMATED","INTERVENTIONAL",[163,164],"PHASE1","PHASE2","The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in two adult populations: Pre Type 2 diabetes (Pre T2D) and Type 2 Diabetes (T2D) in adults who are affected by obesity.",[167],"Overweight and Obesity","2026-05-29",{"date":170,"type":171},"2026-06-02","ACTUAL",{"date":173,"type":171},"2025-01-31",{"date":175,"type":160},"2027-12",{"name":5,"class":6},6]